샘플 요청 목록

 카트 문의
시장보고서
상품코드
1867511

세계의 진균 감염증 진단 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

Fungal Infection Diagnosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 진균 감염증 진단 시장 규모는 2024년에 1억 2,500만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 12.5%로 성장하여 2031년까지 2억 8,100만 달러로 확대될 것으로 예측됩니다.

침습성 진균 감염(IFD)은 진균이 인체 조직이나 혈류에 침입하여 조직 손상, 장기 기능 장애, 염증 반응을 일으키는 심각한 감염을 말합니다. 특히 장기 이식 환자나 암 환자 등 면역력이 저하된 환자에서 발생 빈도가 높으며, 그 발생률은 20%에서 40%에 달하고, 이들 환자군의 주요 사망 원인 중 하나입니다. 조기 진단과 효과적인 치료를 위해 전 세계 대부분의 병원에서는 G 테스트, GM 테스트와 같은 비침습적 검사실 진단 기술을 채택하고 있습니다. 본 보고서에서는 곰팡이 감염 진단에 사용되는 기기 및 시약에 대해 다루며, 특히 G 테스트와 GM 테스트 방법론에 초점을 맞추었습니다.

침습성 진균증(IFD)은 면역 결핍 환자에서 높은 발병률을 보이며, 조기 진단은 여전히 어려운 과제입니다. 현재 G검사, GM검사 등 비침습적 검사법이 곰팡이 감염증의 조기 발견을 위해 전 세계적으로 널리 사용되고 있습니다. 이 방법은 혈청 내 곰팡이 항원을 검출하는 것으로 비교적 신속하고 비침습적인 진단 수단을 제공하며, 특히 면역 억제 상태의 환자에게 적합합니다. 그러나 널리 사용되고 있음에도 불구하고, 이러한 진단법은 민감도와 특이성에 한계가 있으며, 검사자에게 고도의 기술적 전문성이 요구됩니다. 또한, 일부 지역에서는 장비와 시약의 가용성이 여전히 불충분하여 전 세계적인 보급에 걸림돌이 되고 있습니다. 따라서 진단법의 정확도 향상, 비용 절감, 그리고 전 세계적인 보급 확대는 여전히 시급한 과제입니다. 분자생물학, 인공지능, 디지털 병리학의 발전에 따라 진균 감염 진단 분야는 더 높은 효율성, 정확성, 지능화를 향해 나아가고 있습니다. 예를 들어, 딥러닝 알고리즘을 현미경 이미지에 적용하여 염색이 필요 없는 빠르고 정확한 검출을 실현하여 진단 효율과 정확도를 크게 향상시켰습니다. 또한, 디지털 병리 영상 데이터베이스의 구축은 곰팡이 감염의 자동 검출 및 분류에 풍부한 데이터 지원을 제공하여 이 분야의 연구와 응용을 촉진하고 있습니다. 향후 인공지능과 분자진단 기술을 통합한 진단 플랫폼이 진균 감염 진단의 주류가 되어 보다 종합적이고 신속하고 정확한 진단 서비스를 제공할 수 있을 것으로 기대됩니다. 진균 감염 진단 기술의 발전을 이끄는 주요 요인은 조기 진단과 정밀 치료의 시급성입니다. 특히 면역억제 상태의 환자에서는 조기 진단과 적절한 치료가 생존율 향상에 매우 중요합니다. 그러나 기술적 진보에는 몇 가지 장벽이 존재합니다. 첫째, 고급 진단 장비와 시약의 높은 비용으로 인해 자원이 부족한 지역에서의 적용을 제한할 수 있습니다. 둘째, 인공지능과 디지털 병리 기술을 도입하기 위해서는 대량의 고품질 데이터가 필요하지만, 이러한 데이터의 수집과 공유에는 프라이버시 보호와 윤리적 문제가 수반됩니다. 마지막으로, 이러한 기술의 보급과 적용을 위해서는 작업자가 신기술을 확실하게 습득할 수 있도록 해당 교육 및 훈련이 필요합니다. 따라서 비용, 데이터 공유, 인재 육성 등의 과제에 대한 대응이 이 분야 발전의 핵심이 될 것입니다.

이 보고서는 세계 곰팡이 감염 진단 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

곰팡이 감염 진단 시장 규모, 추정치 및 예측치는 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함합니다. 정량적 분석과 정성적 분석을 통해 독자들이 곰팡이 감염 진단 관련 비즈니스/성장 전략을 수립하고, 시장 경쟁을 평가하고, 현재 시장에서의 위치를 분석하고, 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 도와드립니다.

시장 세분화

기업별

  • Associates of Cape Cod
  • Bio-Rad
  • IMMY
  • BioMerieux
  • Fujifilm Wako Pure Chemica
  • Era Biology
  • Dynamiker Biotechnology
  • Zhanjiang A&C Biological
  • Xiamen Bioendo Technology
  • Zhanjiang Bokang Marine Biological
  • Fuzhou XinBei Biochemical Industrial
  • Zhuhai DL Biotech
  • Autobio Diagnostics

유형별 부문

  • Galactomannan Test
  • (1->3)-B-D Glucan Test

용도별 부문

  • 병원
  • 검사실

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동 및 아프리카
LSH 25.12.02

자주 묻는 질문

  • 세계의 진균 감염증 진단 시장 규모는 어떻게 되나요?
  • 침습성 진균 감염의 주요 원인은 무엇인가요?
  • 진균 감염 진단에 사용되는 주요 검사 방법은 무엇인가요?
  • 진균 감염 진단 기술의 발전을 이끄는 주요 요인은 무엇인가요?
  • 진균 감염 진단 시장의 주요 기업은 어디인가요?
  • 진균 감염 진단 시장은 어떤 지역에서 성장하고 있나요?

The global market for Fungal Infection Diagnosis was estimated to be worth US$ 125 million in 2024 and is forecast to a readjusted size of US$ 281 million by 2031 with a CAGR of 12.5% during the forecast period 2025-2031.

Invasive fungal disease (IFD) refers to severe infections caused by fungi invading human tissues and bloodstream, leading to tissue damage, organ dysfunction, and inflammatory responses. It is especially prevalent among immunocompromised patients such as organ transplant recipients and cancer patients, with an incidence rate of 20% to 40%, becoming a significant cause of mortality in these populations. To enable early diagnosis and effective treatment, most hospitals worldwide have adopted non-invasive laboratory diagnostic techniques such as the G test and GM test. This report covers the equipment and reagents used for fungal infection diagnosis, specifically focusing on G test and GM test methodologies.

Invasive fungal diseases (IFDs) have a high incidence among immunocompromised patients, and early diagnosis remains challenging. Currently, non-invasive laboratory diagnostic techniques such as the G test and GM test are widely used globally for early detection of fungal infections. These methods detect fungal antigens in serum, providing relatively rapid and non-invasive diagnostic options, especially suitable for immunosuppressed patients. However, despite their widespread adoption, these diagnostic methods still have limitations in sensitivity and specificity, and require high technical expertise from operators. Additionally, in some regions, the availability of equipment and reagents is still insufficient, limiting their global accessibility. Therefore, improving the accuracy of diagnostic methods, reducing costs, and expanding their availability worldwide remain pressing issues.With advancements in molecular biology, artificial intelligence, and digital pathology, the field of fungal infection diagnosis is moving towards higher efficiency, precision, and intelligence. For instance, deep learning algorithms have been applied to automatically classify and identify fungal species in microscopic images, enabling rapid and accurate detection without the need for staining, significantly improving diagnostic efficiency and accuracy. Moreover, the establishment of digital pathology image databases provides rich data support for automated detection and classification of fungal infections, promoting research and application in this field. In the future, integrated diagnostic platforms combining artificial intelligence and molecular diagnostic technologies are expected to become mainstream in fungal infection diagnosis, offering more comprehensive, rapid, and accurate diagnostic services.The primary driver for the development of fungal infection diagnostic technologies is the urgent need for early diagnosis and precise treatment. Especially among immunosuppressed patients, early diagnosis and timely treatment are crucial for improving survival rates. However, technological advancements face several barriers. Firstly, the high cost of advanced diagnostic equipment and reagents may limit their application in resource-limited areas. Secondly, the application of artificial intelligence and digital pathology technologies requires large amounts of high-quality data, and the acquisition and sharing of such data face challenges related to privacy protection and ethical issues. Lastly, the promotion and application of these technologies require corresponding training and education to ensure operators can proficiently master new technologies. Therefore, addressing issues such as cost, data sharing, and personnel training will be key to advancing this field.

This report aims to provide a comprehensive presentation of the global market for Fungal Infection Diagnosis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Fungal Infection Diagnosis by region & country, by Type, and by Application.

The Fungal Infection Diagnosis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fungal Infection Diagnosis.

Market Segmentation

By Company

  • Associates of Cape Cod
  • Bio-Rad
  • IMMY
  • BioMerieux
  • Fujifilm Wako Pure Chemica
  • Era Biology
  • Dynamiker Biotechnology
  • Zhanjiang A&C Biological
  • Xiamen Bioendo Technology
  • Zhanjiang Bokang Marine Biological
  • Fuzhou XinBei Biochemical Industrial
  • Zhuhai DL Biotech
  • Autobio Diagnostics

Segment by Type

  • Galactomannan Test
  • (1->3)-B-D Glucan Test

Segment by Application

  • Hospital
  • Laboratory

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Fungal Infection Diagnosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Fungal Infection Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Fungal Infection Diagnosis in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Fungal Infection Diagnosis Product Introduction
  • 1.2 Global Fungal Infection Diagnosis Market Size Forecast (2020-2031)
  • 1.3 Fungal Infection Diagnosis Market Trends & Drivers
    • 1.3.1 Fungal Infection Diagnosis Industry Trends
    • 1.3.2 Fungal Infection Diagnosis Market Drivers & Opportunity
    • 1.3.3 Fungal Infection Diagnosis Market Challenges
    • 1.3.4 Fungal Infection Diagnosis Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Fungal Infection Diagnosis Players Revenue Ranking (2024)
  • 2.2 Global Fungal Infection Diagnosis Revenue by Company (2020-2025)
  • 2.3 Key Companies Fungal Infection Diagnosis Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Fungal Infection Diagnosis Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Fungal Infection Diagnosis
  • 2.6 Fungal Infection Diagnosis Market Competitive Analysis
    • 2.6.1 Fungal Infection Diagnosis Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Fungal Infection Diagnosis Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fungal Infection Diagnosis as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Galactomannan Test
    • 3.1.2 (1->3)-B-D Glucan Test
  • 3.2 Global Fungal Infection Diagnosis Sales Value by Type
    • 3.2.1 Global Fungal Infection Diagnosis Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Fungal Infection Diagnosis Sales Value, by Type (2020-2031)
    • 3.2.3 Global Fungal Infection Diagnosis Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Laboratory
  • 4.2 Global Fungal Infection Diagnosis Sales Value by Application
    • 4.2.1 Global Fungal Infection Diagnosis Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Fungal Infection Diagnosis Sales Value, by Application (2020-2031)
    • 4.2.3 Global Fungal Infection Diagnosis Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Fungal Infection Diagnosis Sales Value by Region
    • 5.1.1 Global Fungal Infection Diagnosis Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Fungal Infection Diagnosis Sales Value by Region (2020-2025)
    • 5.1.3 Global Fungal Infection Diagnosis Sales Value by Region (2026-2031)
    • 5.1.4 Global Fungal Infection Diagnosis Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Fungal Infection Diagnosis Sales Value, 2020-2031
    • 5.2.2 North America Fungal Infection Diagnosis Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Fungal Infection Diagnosis Sales Value, 2020-2031
    • 5.3.2 Europe Fungal Infection Diagnosis Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Fungal Infection Diagnosis Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Fungal Infection Diagnosis Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Fungal Infection Diagnosis Sales Value, 2020-2031
    • 5.5.2 South America Fungal Infection Diagnosis Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Fungal Infection Diagnosis Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Fungal Infection Diagnosis Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Fungal Infection Diagnosis Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Fungal Infection Diagnosis Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.3.2 United States Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.4.2 Europe Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.5.2 China Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.6.2 Japan Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.7.2 South Korea Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Fungal Infection Diagnosis Sales Value, 2020-2031
    • 6.9.2 India Fungal Infection Diagnosis Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Fungal Infection Diagnosis Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Associates of Cape Cod
    • 7.1.1 Associates of Cape Cod Profile
    • 7.1.2 Associates of Cape Cod Main Business
    • 7.1.3 Associates of Cape Cod Fungal Infection Diagnosis Products, Services and Solutions
    • 7.1.4 Associates of Cape Cod Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Associates of Cape Cod Recent Developments
  • 7.2 Bio-Rad
    • 7.2.1 Bio-Rad Profile
    • 7.2.2 Bio-Rad Main Business
    • 7.2.3 Bio-Rad Fungal Infection Diagnosis Products, Services and Solutions
    • 7.2.4 Bio-Rad Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Bio-Rad Recent Developments
  • 7.3 IMMY
    • 7.3.1 IMMY Profile
    • 7.3.2 IMMY Main Business
    • 7.3.3 IMMY Fungal Infection Diagnosis Products, Services and Solutions
    • 7.3.4 IMMY Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.3.5 IMMY Recent Developments
  • 7.4 BioMerieux
    • 7.4.1 BioMerieux Profile
    • 7.4.2 BioMerieux Main Business
    • 7.4.3 BioMerieux Fungal Infection Diagnosis Products, Services and Solutions
    • 7.4.4 BioMerieux Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.4.5 BioMerieux Recent Developments
  • 7.5 Fujifilm Wako Pure Chemica
    • 7.5.1 Fujifilm Wako Pure Chemica Profile
    • 7.5.2 Fujifilm Wako Pure Chemica Main Business
    • 7.5.3 Fujifilm Wako Pure Chemica Fungal Infection Diagnosis Products, Services and Solutions
    • 7.5.4 Fujifilm Wako Pure Chemica Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Fujifilm Wako Pure Chemica Recent Developments
  • 7.6 Era Biology
    • 7.6.1 Era Biology Profile
    • 7.6.2 Era Biology Main Business
    • 7.6.3 Era Biology Fungal Infection Diagnosis Products, Services and Solutions
    • 7.6.4 Era Biology Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Era Biology Recent Developments
  • 7.7 Dynamiker Biotechnology
    • 7.7.1 Dynamiker Biotechnology Profile
    • 7.7.2 Dynamiker Biotechnology Main Business
    • 7.7.3 Dynamiker Biotechnology Fungal Infection Diagnosis Products, Services and Solutions
    • 7.7.4 Dynamiker Biotechnology Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Dynamiker Biotechnology Recent Developments
  • 7.8 Zhanjiang A&C Biological
    • 7.8.1 Zhanjiang A&C Biological Profile
    • 7.8.2 Zhanjiang A&C Biological Main Business
    • 7.8.3 Zhanjiang A&C Biological Fungal Infection Diagnosis Products, Services and Solutions
    • 7.8.4 Zhanjiang A&C Biological Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Zhanjiang A&C Biological Recent Developments
  • 7.9 Xiamen Bioendo Technology
    • 7.9.1 Xiamen Bioendo Technology Profile
    • 7.9.2 Xiamen Bioendo Technology Main Business
    • 7.9.3 Xiamen Bioendo Technology Fungal Infection Diagnosis Products, Services and Solutions
    • 7.9.4 Xiamen Bioendo Technology Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Xiamen Bioendo Technology Recent Developments
  • 7.10 Zhanjiang Bokang Marine Biological
    • 7.10.1 Zhanjiang Bokang Marine Biological Profile
    • 7.10.2 Zhanjiang Bokang Marine Biological Main Business
    • 7.10.3 Zhanjiang Bokang Marine Biological Fungal Infection Diagnosis Products, Services and Solutions
    • 7.10.4 Zhanjiang Bokang Marine Biological Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Zhanjiang Bokang Marine Biological Recent Developments
  • 7.11 Fuzhou XinBei Biochemical Industrial
    • 7.11.1 Fuzhou XinBei Biochemical Industrial Profile
    • 7.11.2 Fuzhou XinBei Biochemical Industrial Main Business
    • 7.11.3 Fuzhou XinBei Biochemical Industrial Fungal Infection Diagnosis Products, Services and Solutions
    • 7.11.4 Fuzhou XinBei Biochemical Industrial Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Fuzhou XinBei Biochemical Industrial Recent Developments
  • 7.12 Zhuhai DL Biotech
    • 7.12.1 Zhuhai DL Biotech Profile
    • 7.12.2 Zhuhai DL Biotech Main Business
    • 7.12.3 Zhuhai DL Biotech Fungal Infection Diagnosis Products, Services and Solutions
    • 7.12.4 Zhuhai DL Biotech Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Zhuhai DL Biotech Recent Developments
  • 7.13 Autobio Diagnostics
    • 7.13.1 Autobio Diagnostics Profile
    • 7.13.2 Autobio Diagnostics Main Business
    • 7.13.3 Autobio Diagnostics Fungal Infection Diagnosis Products, Services and Solutions
    • 7.13.4 Autobio Diagnostics Fungal Infection Diagnosis Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Autobio Diagnostics Recent Developments

8 Industry Chain Analysis

  • 8.1 Fungal Infection Diagnosis Industrial Chain
  • 8.2 Fungal Infection Diagnosis Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Fungal Infection Diagnosis Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Fungal Infection Diagnosis Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제